Innate Pharma (IPHA) Long-Term Investments (2017 - 2025)

Innate Pharma has reported Long-Term Investments for 9 years, with the latest figure at $12.2 million in Q4 2025.

• For the quarter ending Q4 2025, Long-Term Investments rose 10.78% year-over-year to $12.2 million; the trailing twelve-month figure through Dec 2025 stood at $12.2 million (up 10.78% YoY), and the FY2025 full-year result was $12.2 million, up 10.78% from the prior year.
• Long-Term Investments for Q4 2025 stood at $12.2 million, up from $11.8 million in the prior quarter.
• The five-year high for Long-Term Investments was $48.3 million in Q2 2021, with the low at $10.5 million in Q4 2023.
• Historically, Long-Term Investments has averaged $26.2 million across 5 years, with a median of $24.0 million in 2022.
• Annual changes were most pronounced in 2021 — Long-Term Investments sank 99.87% — and 2025, when it climbed 10.78%.
• Innate Pharma's Long-Term Investments stood at $45.6 million in 2021, then dropped by 21.46% to $35.8 million in 2022, then plunged by 70.58% to $10.5 million in 2023, then rose by 4.23% to $11.0 million in 2024, then grew by 10.78% to $12.2 million in 2025.
• The last three Long-Term Investments figures came in at $12.2 million (Q4 2025), $11.8 million (Q2 2025), and $11.0 million (Q4 2024), per Business Quant data.